Literature DB >> 11024530

Amelioration of CR-EAE with lisofylline: effects on mRNA levels of IL-12 and IFN-gamma in the CNS.

C Du1, J C Cooper, S J Klaus, S Sriram.   

Abstract

CR-EAE is a Th1-mediated inflammatory autoimmune demyelinating disease of the CNS and serves as a model of human multiple sclerosis. Our previous studies have shown the protective effect of orally administered lisofylline in the prevention of active and passively induced acute EAE. In our present studies we have examined the efficacy and mechanism of action of lisofylline on CR-EAE. Lisofylline decreased the number and severity of paralytic attacks in mice with relapsing EAE. The reduction of clinical disease correlated with decreased levels of mRNA levels of IFN-gamma but not of mRNA levels of IL-12. These studies suggest that lisofylline may be an effective therapeutic for established Th1 mediated autoimmune disease and that it acts by blocking IL-12R signaling and not IL-12 production in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11024530     DOI: 10.1016/s0165-5728(00)00348-9

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

1.  Topical combinations to treat microvascular dysfunction of chronic postischemia pain.

Authors:  André Laferrière; Rachid Abaji; Cheng-Yu Mark Tsai; J Vaigunda Ragavendran; Terence J Coderre
Journal:  Anesth Analg       Date:  2014-04       Impact factor: 5.108

2.  Topical combinations aimed at treating microvascular dysfunction reduce allodynia in rat models of CRPS-I and neuropathic pain.

Authors:  J Vaigunda Ragavendran; André Laferrière; Wen Hua Xiao; Gary J Bennett; Satyanarayana S V Padi; Ji Zhang; Terence J Coderre
Journal:  J Pain       Date:  2013-01       Impact factor: 5.820

3.  Interleukin-23 Mediates Osteoclastogenesis in Collagen-Induced Arthritis by Modulating MicroRNA-223.

Authors:  Shih-Yao Chen; Ting-Chien Tsai; Yuan-Tsung Li; Yun-Chiao Ding; Chung-Teng Wang; Jeng-Long Hsieh; Chao-Liang Wu; Po-Ting Wu; Ai-Li Shiau
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.